San Diego, CA, United States of America

Andre K Kiryanov

This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andre K Kiryanov. Retrieved from https://idiyas.com/inventor/andre-k-kiryanov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Andre K Kiryanov

Introduction

Andre K Kiryanov is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit poly (ADP-ribose) polymerase (PARP). His work is crucial in advancing treatments for various diseases.

Latest Patents

Kiryanov holds a patent for Poly (ADP-ribose) polymerase (PARP) inhibitors. The patent details compounds of a specific formula designed for use with PARP, along with pharmaceutical compositions, kits, and articles of manufacture that include these compounds. Additionally, the patent outlines methods and intermediates useful for creating these compounds, as well as methods for utilizing them effectively.

Career Highlights

Kiryanov is associated with Takeda Pharmaceutical Company Limited, where he continues to innovate and contribute to the pharmaceutical industry. His expertise in PARP inhibitors showcases his commitment to advancing medical science and improving patient outcomes.

Collaborations

He has collaborated with notable colleagues, including Jason W Brown and Anthony R Gangloff, to further enhance the research and development of pharmaceutical solutions.

Conclusion

Andre K Kiryanov's work in developing PARP inhibitors represents a significant advancement in the pharmaceutical field. His contributions are vital for the ongoing research and development of effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…